Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy.

Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Abstract Text:

J Daniel Pennington,Kristi Muldoon Jacobs,Lunching Sun,Gil Bar-Sela,Mark Mishra,David Gius,J Daniel Pennington,Kristi Muldoon Jacobs,Lunching Sun,Gil Bar-Sela,Mark Mishra,David Gius,

Tumor cell proliferation, de-differentiation, and progression depend on a complex combination of altered intracellular processes including cell cycle regulation, excessive growth factor pathway activation, and decreased apoptosis. Metabolites from these processes result in significant cellular oxidative stress that must be buffered to prevent permanent cell damage and cell death. Tumor cells depend on a complex set of respiratory pathways to generate the necessary energy as well as redox-sensitive pro-survival signaling pathways and factors to cope with and defend against the detrimental effects of oxidative stress. It has been hypothesized that redox-sensitive signaling factors such as thioredoxin reductase-1 (TR) and thioredoxin (TRX) may represent central pro-survival factors that would allow tumor cells to evade the damaging and potentially cytotoxic effects of endogenous and exogenous agents that induce oxidative stress. The overarching theme of this review is an extension of the hypothesis that tumor cells use these redox sensitive pro-survival signaling pathways/factors, which are up-regulated due to increased tumor cell respiration, to evade the cytotoxic effects of anticancer agents. These observations suggest that redox-sensitive signaling factors may be potential novel molecular targets for drug discovery.

Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Publishing Authors By Initials

JD Pennington,KM Jacobs,L Sun,G Bar-Sela,M Mishra,D Gius,JD Pennington,KM Jacobs,L Sun,G Bar-Sela,M Mishra,D Gius,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Intr

Journal: Current pharmaceutical design

VOLUME: 13

Page Numbers: 3368-77

Journal Abbreviation: Curr. Pharm. Des.

ISSN: 1873-4286

DAY: 29

MONTH: 11

YEAR: 2007

Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9602487

Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy.

AFFILIATION: Molecular Radiation Oncology Section, Radiation Oncology Branch, Radiation Oncology Sciences Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

Country: Netherlands

AGENCY: United States NIDDK

GRANT: DK51612

ACRONYM: DK

MEDLINETA: Curr Pharm Des

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy Related Publications

• BAT3 and SET1A Form a Complex with CTCFL/BORIS To Modulate H3K4 Histone Dimethylation and Gene Expression.
• CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region.
• DNA methyltransferase 1 and 3B activate BAG-1 expression via recruitment of CTCFL/BORIS and modulation of promoter histone methylation.
• DNMT1 as a Molecular Target in a Multimodality-Resistant Phenotype in Tumor Cells.
• SIRT3 interacts with the daf-16 homolog FOXO3a in the Mitochondria, as well as increases FOXO3a Dependent Gene expression.
• Some observations on vascular adjustments following interruption of major venous channels.
• The role of hypertrophy of the muscularis in the delayed onset of symptoms in cancer of the colon.
• Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy.